INTS · Intensity Therapeutics, Inc.
$3.96
-0.04 (-1.00%)
At close · Aug 14
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our balances in cash and cash equivalents, our ability to continue our operations is dependent on obtaining additional capital, which is not within our control. As a result, we believe there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$12.93M
Shares
3.26M
Intensity Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Intensity Therapeutics, Inc. (INTS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Annual General Meeting
Investor event
2026-12-31
2026 Annual Meeting of Stockholders
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-11
Second Quarter 2026 Financial Results Conference Call
Positive tone
Invincible 3 (Phase III ovarian)
European regulatory submission
Capital and funding
Diluted EPS
$-1.11
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Intensity Therapeutics, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-35.75
Audio
Transcript
Slides
8-K10-Q
Showing 1–3 of 3 earnings calls
Key facts
CIK
1567264
CUSIP
45828J202
13F (30d)
15 filings
15 filers
Visit website
Investor relations